CURR ATHEROSCLER REP 润色咨询

Current Atherosclerosis Reports

出版年份：暂无数据 年文章数：689 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：1.6% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2201186, encodeId=1d7c220118625, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：血管外科;非约稿综述;主动脉瘤<br>经验分享：自投综述，在编辑手里拖了三个多月，审稿人审了一个月左右接收<br>Submission is in publishing and rights<br>24 Apr 2024<br>Peer review<br>Submission accepted<br>24 Apr 2024<br>Submission under peer review<br>22 Mar 2024<br>Submission passed technical check<br>22 Mar 2024<br>Revision received<br>21 Mar 2024<br>Submission under peer review<br>05 Dec 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>05 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ac6575208, createdName=ms9000001429548900, createdTime=Tue Apr 30 08:39:45 CST 2024, time=2024-04-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1250243, encodeId=ecaf125024347, content=综述都是约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e95d2111381, createdName=若曦jennifer, createdTime=Sat Sep 17 13:14:34 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101437, encodeId=30d6110143e70, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101438, encodeId=8ede110143857, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=538978, encodeId=8b7e5389e873, content=过去不错的，现在这么跌下去，很吓人。明年想再回到3分水平，也许真心太难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=338, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=med_wu, createdTime=Tue Jul 18 18:23:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492616, encodeId=d6604926164d, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2024-04-30 ms9000001429548900 来自北京

    审稿速度:6.0 | 投稿命中率:75.0
    偏重的研究方向：血管外科;非约稿综述;主动脉瘤
    经验分享：自投综述，在编辑手里拖了三个多月，审稿人审了一个月左右接收
    Submission is in publishing and rights
    24 Apr 2024
    Peer review
    Submission accepted
    24 Apr 2024
    Submission under peer review
    22 Mar 2024
    Submission passed technical check
    22 Mar 2024
    Revision received
    21 Mar 2024
    Submission under peer review
    05 Dec 2023
    Technical check
    Submission status Date
    Submission passed technical check
    05 Dec 2023
    Submission is under technical check
    04 Dec 2023
    Submission received
    Submission status Date
    Submission received
    04 Dec 2023

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2201186, encodeId=1d7c220118625, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：血管外科;非约稿综述;主动脉瘤<br>经验分享：自投综述，在编辑手里拖了三个多月，审稿人审了一个月左右接收<br>Submission is in publishing and rights<br>24 Apr 2024<br>Peer review<br>Submission accepted<br>24 Apr 2024<br>Submission under peer review<br>22 Mar 2024<br>Submission passed technical check<br>22 Mar 2024<br>Revision received<br>21 Mar 2024<br>Submission under peer review<br>05 Dec 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>05 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ac6575208, createdName=ms9000001429548900, createdTime=Tue Apr 30 08:39:45 CST 2024, time=2024-04-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1250243, encodeId=ecaf125024347, content=综述都是约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e95d2111381, createdName=若曦jennifer, createdTime=Sat Sep 17 13:14:34 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101437, encodeId=30d6110143e70, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101438, encodeId=8ede110143857, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=538978, encodeId=8b7e5389e873, content=过去不错的，现在这么跌下去，很吓人。明年想再回到3分水平，也许真心太难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=338, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=med_wu, createdTime=Tue Jul 18 18:23:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492616, encodeId=d6604926164d, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2022-09-17 若曦jennifer

    综述都是约稿吗？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2201186, encodeId=1d7c220118625, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：血管外科;非约稿综述;主动脉瘤<br>经验分享：自投综述，在编辑手里拖了三个多月，审稿人审了一个月左右接收<br>Submission is in publishing and rights<br>24 Apr 2024<br>Peer review<br>Submission accepted<br>24 Apr 2024<br>Submission under peer review<br>22 Mar 2024<br>Submission passed technical check<br>22 Mar 2024<br>Revision received<br>21 Mar 2024<br>Submission under peer review<br>05 Dec 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>05 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ac6575208, createdName=ms9000001429548900, createdTime=Tue Apr 30 08:39:45 CST 2024, time=2024-04-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1250243, encodeId=ecaf125024347, content=综述都是约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e95d2111381, createdName=若曦jennifer, createdTime=Sat Sep 17 13:14:34 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101437, encodeId=30d6110143e70, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101438, encodeId=8ede110143857, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=538978, encodeId=8b7e5389e873, content=过去不错的，现在这么跌下去，很吓人。明年想再回到3分水平，也许真心太难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=338, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=med_wu, createdTime=Tue Jul 18 18:23:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492616, encodeId=d6604926164d, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2021-12-28 Mia

    上传文章有什么要求？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2201186, encodeId=1d7c220118625, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：血管外科;非约稿综述;主动脉瘤<br>经验分享：自投综述，在编辑手里拖了三个多月，审稿人审了一个月左右接收<br>Submission is in publishing and rights<br>24 Apr 2024<br>Peer review<br>Submission accepted<br>24 Apr 2024<br>Submission under peer review<br>22 Mar 2024<br>Submission passed technical check<br>22 Mar 2024<br>Revision received<br>21 Mar 2024<br>Submission under peer review<br>05 Dec 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>05 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ac6575208, createdName=ms9000001429548900, createdTime=Tue Apr 30 08:39:45 CST 2024, time=2024-04-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1250243, encodeId=ecaf125024347, content=综述都是约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e95d2111381, createdName=若曦jennifer, createdTime=Sat Sep 17 13:14:34 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101437, encodeId=30d6110143e70, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101438, encodeId=8ede110143857, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=538978, encodeId=8b7e5389e873, content=过去不错的，现在这么跌下去，很吓人。明年想再回到3分水平，也许真心太难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=338, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=med_wu, createdTime=Tue Jul 18 18:23:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492616, encodeId=d6604926164d, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2021-12-28 rayms

    如何判断两种药物之间是协同作用还是相加作用？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2201186, encodeId=1d7c220118625, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：血管外科;非约稿综述;主动脉瘤<br>经验分享：自投综述，在编辑手里拖了三个多月，审稿人审了一个月左右接收<br>Submission is in publishing and rights<br>24 Apr 2024<br>Peer review<br>Submission accepted<br>24 Apr 2024<br>Submission under peer review<br>22 Mar 2024<br>Submission passed technical check<br>22 Mar 2024<br>Revision received<br>21 Mar 2024<br>Submission under peer review<br>05 Dec 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>05 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ac6575208, createdName=ms9000001429548900, createdTime=Tue Apr 30 08:39:45 CST 2024, time=2024-04-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1250243, encodeId=ecaf125024347, content=综述都是约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e95d2111381, createdName=若曦jennifer, createdTime=Sat Sep 17 13:14:34 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101437, encodeId=30d6110143e70, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101438, encodeId=8ede110143857, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=538978, encodeId=8b7e5389e873, content=过去不错的，现在这么跌下去，很吓人。明年想再回到3分水平，也许真心太难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=338, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=med_wu, createdTime=Tue Jul 18 18:23:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492616, encodeId=d6604926164d, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2017-07-18 med_wu

    过去不错的，现在这么跌下去，很吓人。明年想再回到3分水平，也许真心太难。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2201186, encodeId=1d7c220118625, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：血管外科;非约稿综述;主动脉瘤<br>经验分享：自投综述，在编辑手里拖了三个多月，审稿人审了一个月左右接收<br>Submission is in publishing and rights<br>24 Apr 2024<br>Peer review<br>Submission accepted<br>24 Apr 2024<br>Submission under peer review<br>22 Mar 2024<br>Submission passed technical check<br>22 Mar 2024<br>Revision received<br>21 Mar 2024<br>Submission under peer review<br>05 Dec 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>05 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ac6575208, createdName=ms9000001429548900, createdTime=Tue Apr 30 08:39:45 CST 2024, time=2024-04-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1250243, encodeId=ecaf125024347, content=综述都是约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e95d2111381, createdName=若曦jennifer, createdTime=Sat Sep 17 13:14:34 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101437, encodeId=30d6110143e70, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101438, encodeId=8ede110143857, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=538978, encodeId=8b7e5389e873, content=过去不错的，现在这么跌下去，很吓人。明年想再回到3分水平，也许真心太难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=338, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=med_wu, createdTime=Tue Jul 18 18:23:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492616, encodeId=d6604926164d, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2012-11-28 qupeter

    明年能不能冲到3分？大家谈谈

    0

共9条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分